Rheumatoid Arthritis Archives - Infectious Disease Advisor

Case Report: Tuberculous Arthritis of Ankle Joint Mimics RA in Patient With Lupus Nephritis

By

Amit Akirov, MD

March 15, 2021

In this case study, the authors highlighted the importance of tuberculous arthritis in the differential diagnoses of patients with persistent ankle swelling.

COVID19

ACR Releases COVID-19 Vaccine Clinical Guidance for Patients With Rheumatic and Musculoskeletal Diseases

By

Inga Back, MPH

March 5, 2021

The American College of Rheumatology developed clinical guidance for the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases.

General Infectious Disease

Risk Score Predictive of Serious Infections in Patients With Rheumatoid Arthritis

By

Sheila Jacobs

February 25, 2021

Researchers identified risk factors for serious infections in rheumatoid arthritis and validated the RABBIT risk score in real-life settings.

General Infectious Disease

Infection Risk During Targeted and Biologic Therapies in Rheumatoid Arthritis and Psoriatic Arthritis

By

Tori Rodriguez, MA, LPC, AHC

November 25, 2020

An overview of the risk for infections during targeted and biological therapies in rheumatoid arthritis and psoriatic arthritis.

COVID19

Assessing the Effect of Antimalarial Drug Shortages in Rheumatic Disease During the COVID-19 Pandemic

By

Chen Fang, PharmD, RPh

November 23, 2020

The COVID-19 Global Rheumatology Alliance Patient Experience Survey was used to assess the effect of antimalarial drug shortages during the COVID-19 pandemic.

COVID19

Maintaining Treat-to-Target Strategies for Rheumatoid Arthritis During the COVID-19 Pandemic

By

Emily Pond

September 25, 2020

Treat-to-target and safe tapering strategies have been considered essential in the management of rheumatoid arthritis.

Prevention

Rates of Serious Infection Events Similar With Upadacitinib, Adalimumab in Rheumatoid Arthritis

By

Hannah Dellabella

December 10, 2019

In study data presented at the 2019 ACR Annual Meeting, researchers evaluated the overall safety of upadacitinib as monotherapy and combination therapy with background disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis.

Prevention

Slightly Increased Serious Infection Risk With Biologic vs Synthetic DMARDs in RA

By

Infectious Disease Advisor Contributing Writer

November 26, 2019

Researchers assessed the most recent safety data of synthetic and biologic disease-modifying antirheumatic drugs to inform the 2019 update of the European League Against Rheumatism recommendations for the management of rheumatoid arthritis.